Replies to post #11437 on RespireRx Pharmaceuticals Inc (fka RSPI)

[Market_Fest4]

I believe the problem lies in quantifying the extent to which someone suffers from MCI and the endpoint to prove improvement. It's very subjective.
MF4

[gfp927z]

Concerning MCI, that was with the ultra weak CX-516, so it was doomed from the start. Servier then tried their own S-18986, but that compound is a dog, one of Servier's benzothiadiazides. Unfortunately, we never got the chance to target MCI with a potent low impact like CX-717.

When MCI was originally recognized by the FDA as a new clinical indication for drug development, there was a lot of enthusiasm, but as an indication it's now faded considerably. MCI is now seen as one of those fuzzy indications where the path to approval is difficult.